Abstract
Objective
To determine if arterial-spin-labelling (ASL) MRI can reliably detect early response to anti-angiogenic therapy in patients with multiple myeloma by comparison with clinical/haematological response.
Methods
Nineteen consecutive patients (10 men; mean age 63.5 ± 9.1 years) were included in the present study. Inclusion criteria were diagnosis of stage III multiple myeloma and clinical indication for therapeutical administration of bortezomib or lenalidomide. We performed MRI on 3.0T MR in the baseline setting, 3 weeks after onset of therapy and after 8 weeks. Clinical responses were determined on the basis of international uniform response criteria in correlation with haematological parameters and medium-term patient outcome. MRI studies were performed after approval by the local institutional review board.
Results
Fifteen patients responded to anti-myeloma therapy; 4/19 patients were non-responders to therapy. Mean tumour perfusion assessed by ASL-MRI in a reference lesion was 220.7 ± 132.5 ml min−1 100 g−1 at baseline, and decreased to 125.7 ± 86.3 (134.5 ± 150.9) ml min−1 100 g−1 3 (8) weeks after onset of therapy (P < 0.02). The mean decrease in paraproteinaemia at week 3 (8) was 52.3 ± 47.7% (58.2 ± 58.7%), whereas β2-microglobulinaemia decreased by 20.3 ± 53.1% (23.3 ± 57.0%). Correlation of ASL perfusion with outcome was significant (P = 0.0037).
Conclusion
ASL tumour perfusion measurements are a valuable surrogate parameter for early assessment of response to novel anti-angiogenic therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kumar S, Fonseca R, Dispenzieri A et al (2002) Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 119:665–671
Pruneri G, Ponzoni M, Ferreri AJ et al (2002) Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 118:817–820
Lin C, Luciani A, Belhadj K et al (2009) Patients with plasma cell disorders examined at whole-body dynamic contrast-enhanced MR imaging: initial experience. Radiology 250:905–915
Pollock JM, Tan H, Kraft RA et al (2009) Arterial spin-labeled MR perfusion imaging: clinical applications. Magn Reson Imaging Clin N Am 17:315–338
Blade J, Samson D, Reece D et al (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115–1123
Montazel J, Divine M, Lepage E et al (2003) Normal spinal bone marrow in adults: dynamic gadolinium-enhanced MR imaging. Radiology 229:703–709
Takeuchi M, Matsuzaki K Nishitani H (2009) Diffusion-weighted magnetic resonance imaging of endometrial cancer: differentiation from benign endometrial lesions and preoperative assessment of myometrial invasion. Acta Radiol 1:1–7
Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 28(351):1860–1873
Anderson KC (2003) Multiple myeloma: how far have we come? Mayo Clin Proc 78:15–17
Attal M, Harousseau JL, Facon T et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495–2502
Hideshima T, Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2:927–937
Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498
Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617
Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063–3067
Davies FE, Raje N, Hideshima T et al (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210–216
Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943–2950
Horger M, Pereira P, Claussen CD et al (2008) Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. Br J Radiol 81:386–396
Walker R, Barlogie B, Haessler J et al (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 25:1121–1128
Angtuaco EJ, Fassas AB, Walker R et al (2004) Multiple myeloma: clinical review and diagnostic imaging. Radiology 231:11–23
Warmuth C, Gunther M, Zimmer C (2003) Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 228:523–532
Schor-Bardach R, Alsop DC, Pedrosa I et al (2009) Does arterial spin-labeling MR imaging–measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 251:731–742
Rahmouni A, Montazel JL, Divine M et al (2003) Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. Radiology 229:710–717
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fenchel, M., Konaktchieva, M., Weisel, K. et al. Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results. Eur Radiol 20, 2899–2906 (2010). https://doi.org/10.1007/s00330-010-1870-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-010-1870-z